The Oncogenomics Handbook [electronic resource] /
LaRochelle, William J.editor.
Shimkets, Richard A.editor.
Bioinformatic integration of the findings from recent genomic and proteomic research has made possible the development of highly selective therapeutics that can target specific cellular pathways controlling cell proliferation, differentiation, metastasis, evasion of immune surveillance, angiogenesis, and apoptosis. In The Oncogenomics Handbook, a panel of internationally recognized researchers and clinicians provides an integrated overview of cancer drug discovery and development from the bench to the clinic, showing with broad strokes and representative examples the drug development process as a network of linked components leading from the discovered target to the ultimate therapeutic product. Following that path, the authors explain genomic databases and how to discover oncological targets from them, how then to advance from the gene and transcript to the level of protein biochemistry, how next to move from the chemical realm to that of the living cell and, ultimately, pursue animal modeling and clinical development. Emerging cancer therapeutics including rituximab, Herceptin®, Avastin™, ABGX-EGF, Velcade®, Iressa®, and Zevalin® are addressed. Additional chapters review clinical diagnostics, bioanalytics, and biomarkers and their importance to therapeutic outcome; detail antiangiogenic, supportive, immunomodulatory, and tumor-targeted approaches to cancer therapy; and provide a systems biology-bioinformatics overview of strategies and initiatives for the postgenomic era. Highlights include cancer genomics, transcriptomics, gene expression analysis, proteomic and enzymatic cancer profiling technologies, and cellular and animal approaches to cancer target validation. Authoritative and state-of-the-art, The Oncogenomics Handbook offers cancer researchers and drug developers a comprehensive update on the contribution of the genomic revolution to cancer drug discovery and development.
Description based upon print version of record.
Includes bibliographical references and index.
Genomics, Cancer Targets, Transcriptomics, and Gene Expression Analysis -- Genomic Resources for Cancer Biologists -- Cancer Drug Target Identification by SAGE, LongSAGE, and Digital Karyotyping -- Identification of Novel Cancer Target Antigens Utilizing EST and Genome Sequence Databases -- Tree-Based Cancer Classification and Diagnosis Using Gene Expression Data -- From FISH to Proteomics -- Gene Program Signatures for Papillomavirus E2-Mediated Senescence in Cervical Cancer Cells -- Advances in Proteomic and Enzymatic Cancer-Profiling Technologies -- Mass-Spectrometry-Based Proteomics for Cancer Biology -- Chemical Proteomics in Drug Development -- Proteomics-Based Anticancer Drug Discovery -- Cancer Metabolic Phenotype -- Focusing Target Discovery and Validation Through Proteogenomics and Molecular Imaging -- Cancer Target Validation: Cellular Approaches -- RNA Interference -- Image-Based Assays of Cellular Phenotype for Drug Target Discovery and Validation -- Targeting Inducible Chemotherapy Resistance Mechanisms in Colon Cancer -- Targeting Apoptosis Pathways for Cancer Therapy -- Cancer Target Validation: Animal Approaches -- Genetically Engineered Mouse Models of Human Cancer for Drug Discovery and Development -- Unraveling the Complexity of Oncogenesis Through In Vivo Optical Imaging -- Innovative Strategies for Improving Engineered Mouse Models of Human Cancer for Preclinical Development -- Use of Adenovirus-Mediated Gene Transfer to Facilitate Biological Annotation of Novel Genes -- Cancer Biology and Transgenic Technology in the Mouse -- Homology-Based Genomic Mining of Growth Factors Implicated in Neoplasia and Nephritides -- Cancer Prognostics, Diagnostics, and Biomarkers -- Cancer Pharmacogenomics -- Diagnosis and Treatment of Malignancies Using Gene Expression Profiling -- Implications of Epigenetics for Early Cancer Diagnosis and Prevention -- Novel Molecular and Genetic Prognostic Biomarkers in Prostate Cancer -- PSA in Prostate Cancer Diagnosis -- Tumor Targets and Biomarkers in Renal Cell Carcinoma -- Emerging Approaches to Cancer Therapy -- Tumor Vasculature as a Target for Cancer Therapy -- Targeting the VEGF/VEGFR Axis for Cancer Therapy -- Inhibiting Cancer Angiogenesis With Molecular Therapy -- Development of Palifermin (rHuKGF) for Mucositis -- Immune Modulations -- Proteasome Inhibition and Its Clinical Application in Solid Tumors -- Tumor Necrosis Factor Family of Ligands and Receptors in Cancer Therapy -- Small-Molecule Receptor Tyrosine Kinase Inhibitors in Targeted Cancer Therapy -- The mTOR Pathway and Its Inhibitors -- Cyclo-Oxygenase-2 Enzyme and Its Inhibition in Tumor Growth and Therapy -- Understanding Prostate-Specific Membrane Antigen and Its Implication in Prostate Cancer -- Development of a Radiolabeled Monoclonal Antibody to Prostate-Specific Membrane Antigen -- Monoclonal Antibody Strategies for Targeting HER2 -- From XenoMouse® Technology to Panitumumab (ABX-EGF) -- Development and Evaluation of Cancer Therapeutic Agents Targeting TRAIL Receptor 1 and 2 -- Clinical Studies of Immunotherapy With Rituximab (Rituxan®) and Radioimmunotherapy With Ibritumomab Tiuxetan (Zevalin®) in B-Cell Lymphoid Malignancies -- Informatics Strategies and Initiatives -- Informatics Strategies and Initiatives Used in Cancer Research.
Bioinformatic integration of the findings from recent genomic and proteomic research has made possible the development of highly selective therapeutics that can target specific cellular pathways controlling cell proliferation, differentiation, metastasis, evasion of immune surveillance, angiogenesis, and apoptosis. In The Oncogenomics Handbook, a panel of internationally recognized researchers and clinicians provides an integrated overview of cancer drug discovery and development from the bench to the clinic, showing with broad strokes and representative examples the drug development process as a network of linked components leading from the discovered target to the ultimate therapeutic product. Following that path, the authors explain genomic databases and how to discover oncological targets from them, how then to advance from the gene and transcript to the level of protein biochemistry, how next to move from the chemical realm to that of the living cell and, ultimately, pursue animal modeling and clinical development. Emerging cancer therapeutics including rituximab, Herceptin®, Avastin™, ABGX-EGF, Velcade®, Iressa®, and Zevalin® are addressed. Additional chapters review clinical diagnostics, bioanalytics, and biomarkers and their importance to therapeutic outcome; detail antiangiogenic, supportive, immunomodulatory, and tumor-targeted approaches to cancer therapy; and provide a systems biology-bioinformatics overview of strategies and initiatives for the postgenomic era. Highlights include cancer genomics, transcriptomics, gene expression analysis, proteomic and enzymatic cancer profiling technologies, and cellular and animal approaches to cancer target validation. Authoritative and state-of-the-art, The Oncogenomics Handbook offers cancer researchers and drug developers a comprehensive update on the contribution of the genomic revolution to cancer drug discovery and development.
Oncology  .
Oncology.
Cancer Drug Discovery and Development